1. Scrip
  2. >>Business

Investors Back iOmx’s Focus On Tumor Immune Evasion

Developing Anti-Immune Evasion Platform

 
• By Andrew McConaghie

The German biopharmaceutical company has been around since 2016, but now has the funding to bring its first candidate into clinical trials by late 2022

Euro symbol, Frankfurt
The consortium's funding of €65m will see iOmx's lead candidate through its Phase I development.

iOmx Therapeutics, a German biopharma company developing cancer therapies based on next generation immune checkpoint targets, has announced the closing of a series B round totaling €65m.

Investors have backed the Martinsried, Munich-headquartered company because of the potential they see for its scientific approach to expand

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.